The estimated Net Worth of Anil Diwan is at least $5.49 Millón dollars as of 22 September 2015. Anil Diwan owns over 208,771 units of NanoViricides Inc stock worth over $3,394,165 and over the last 11 years he sold NNVC stock worth over $1,502,360. In addition, he makes $589,038 as Executive Chairman of the Board y President at NanoViricides Inc.
Anil has made over 7 trades of the NanoViricides Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 208,771 units of NNVC stock worth $73,070 on 22 September 2015.
The largest trade he's ever made was exercising 208,771 units of NanoViricides Inc stock on 22 September 2015 worth over $73,070. On average, Anil trades about 76,092 units every 88 days since 2013. As of 22 September 2015 he still owns at least 2,082,310 units of NanoViricides Inc stock.
You can see the complete history of Anil Diwan stock trades at the bottom of the page.
Dr. Anil Diwan Ph.D. serves as Executive Chairman of the Board, President of the Company. Dr. Diwan has been President and the Chairman of the Board of Directors of the Company since consummation of the merger on June 1, 2005. Dr. Diwan simultaneously therewith and since its formation, has also served as the Chief Executive Officer and Director of AllExcel, Inc. (from 1995 to the present) and TheraCour Pharma, Inc. (from 2004 to the present) and is the original inventor of the technologies licensed to NanoViricides Inc., as well as the TheraCour polymeric micelle technologies and products based on them. Since 1992, he has researched and developed TheraCour nanomaterials. Dr. Diwan was the first to propose the development of novel pendant polymers for drug delivery that led to an explosion of research in pharmacological applications of polymeric micelles. Anil has won over 12 NIH SBIR grants. Dr. Diwan holds several issued patents, and three international patent applications in various stages of prosecution in a number of countries, and has made intellectual property depositions of several additional patentable discoveries with the patent attorney. Dr. Diwan has been intimately involved in the Company’s Scientific as well as Business Affairs, including, but not limited to development of external collaborations as well as financings. Dr. Diwan spear-headed the up-listing of the Company to NYSE-American exchange in 2013. Dr. Diwan has held several scholastic distinctions, including an All-India 9th rank on the Joint Entrance Examination of all IIT’s. He holds a Ph.D. in Biochemical Engineering from Rice University (1986) and B.S. in Chemical Engineering from Indian Institute of Technology (IIT) Bombay (1980).
As the Executive Chairman of the Board y President of NanoViricides Inc, the total compensation of Anil Diwan at NanoViricides Inc is $589,038. There are no executives at NanoViricides Inc getting paid more.
Anil Diwan is 61, he's been the Executive Chairman of the Board y President of NanoViricides Inc since 2019. There are 6 older and 2 younger executives at NanoViricides Inc. The oldest executive at NanoViricides Inc is Stanley Glick, 85, who is the Independent Director.
Anil's mailing address filed with the SEC is C/O NANOVIRICIDES, INC.,, 1 CONTROL DRIVE, SHELTON, CT, 06484.
Over the last 15 years, insiders at NanoViricides Inc have traded over $1,608,110 worth of NanoViricides Inc stock and bought 1,581,444 units worth $2,879,162 . The most active insiders traders include Milton Boniuk, Anil Diwan y Pharma, Inc. Theracour. On average, NanoViricides Inc executives and independent directors trade stock every 77 days with the average trade being worth of $126,113. The most recent stock trade was executed by Milton Boniuk on 11 November 2015, trading 25,000 units of NNVC stock currently worth $30,000.
nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir
NanoViricides Inc executives and other stock owners filed with the SEC include: